Cargando…
Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer
In the quest for markers of expression and progression for prostate cancer (PCa), the majority of studies have focussed on molecular data exclusively from primary tumours. Although expression in metastases is inferred, a lack of correlation with secondary tumours potentially limits their applicabili...
Autores principales: | Landers, K A, Samaratunga, H, Teng, L, Buck, M, Burger, M J, Scells, B, Lavin, M F, Gardiner, R A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527792/ https://www.ncbi.nlm.nih.gov/pubmed/18648369 http://dx.doi.org/10.1038/sj.bjc.6604486 |
Ejemplares similares
-
Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity
por: Tittarelli, A, et al.
Publicado: (2015) -
DKC1 overexpression associated with prostate cancer progression
por: Sieron, P, et al.
Publicado: (2009) -
EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205
por: Massoner, P, et al.
Publicado: (2014) -
UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas
por: Pallante, P, et al.
Publicado: (2005) -
Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials
por: Som, A, et al.
Publicado: (2012)